p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells by Brugarolas, James et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/98/04/503/12 $2.00
The Journal of Cell Biology, Volume 141, Number 2, April 20, 1998 503–514
http://www.jcb.org 503
 
p21 Is a Critical CDK2 Regulator Essential for
Proliferation Control in 
 
Rb
 
-deficient Cells
 
James Brugarolas,* Roderick T. Bronson,
 
§
 
 and Tyler Jacks*
 
‡
 
*Department of Biology, Center for Cancer Research, 
 
‡
 
Howard Hughes Medical Institute, Massachusetts Institute of 
Technology, Cambridge, Massachusetts 02139; and 
 
§
 
Department of Pathology, Tufts University, Boston, Massachusetts 02111
 
Abstract. 
 
Proliferation in mammalian cells is con-
trolled primarily in the G1-phase of the cell cycle 
through the action of the G1 cyclin–dependent kinases, 
CDK4 and CDK2. To explore the mechanism of cellu-
lar response to extrinsic factors, specific loss of function 
mutations were generated in two negative regulators of 
G1 progression, p21 and pRB. Individually, these muta-
tions were shown to have significant effects in G1 regu-
lation, and when combined, 
 
Rb
 
 and 
 
p21
 
 mutations 
caused more profound defects in G1. Moreover, cells 
deficient for pRB and p21 were uniquely capable of an-
chorage-independent growth. In contrast, combined 
absence of pRB and p21 function was not sufficient to 
overcome contact inhibition of growth nor for tumor 
formation in nude mice. Finally, animals with the geno-
 
type 
 
Rb
 
1/2
 
;
 
p21
 
2/2
 
 succumbed to tumors more rapidly 
than 
 
Rb
 
1/2
 
 mice, suggesting that in certain contexts 
mutations in these two cell cycle regulators can cooper-
ate in tumor development.
 
T
 
he
 
 hallmark of cancer is uncontrolled cell prolifera-
tion (for review see Sherr, 1996). Proliferation con-
trol, manifested by the integration and coordination
of extracellular signals with the cell cycle machinery, is lost
in tumor cells. Tumor cells proliferate autonomously; they
are less dependent on growth-promoting signals and also
less responsive to growth inhibitory signals. Numerous tis-
sue culture assays have been developed that underscore
these aspects of cellular transformation. For example, tu-
mor cells grow at concentrations of growth factors insuffi-
cient for normal cell proliferation (Holley and Kiernan,
1968; Dulbecco, 1970; Jainchill and Todaro, 1970). They
are also anchorage-independent for growth (MacPherson
and Montagnier, 1964; Sanders and Burford, 1964) and
less susceptible to contact inhibition than wild-type cells
(Temin and Rubin, 1958; Todaro et al., 1963; Vogt and
Dulbecco, 1963; Dulbecco, 1970).
The enzymes that regulate cell cycle progression, the cy-
clin-dependent kinases (CDKs)
 
1
 
 are candidates to inte-
grate growth control signals with the cell cycle machinery
(for review see Sherr, 1996). These enzymes, which are
composed of a catalytic kinase subunit and a regulatory
subunit called cyclin, are regulated by multiple mecha-
nisms, including the rate of synthesis, subcellular localiza-
tion and degradation rate of the cyclin subunit (for review
see Morgan, 1995). CDK activity is also regulated by stim-
ulatory and inhibitory phosphorylation events (for review
see Morgan, 1995) as well as by the binding of cyclin-
dependent kinase inhibitors (CKIs; for review see Peter,
1994). There are two families of CKIs, the Cip/Kip family
and the InK4 family (for review see Sherr and Roberts,
1995). The Cip/Kip family consists of p21, p27, and p57
and is characterized by a conserved NH
 
2
 
-terminal CDK-
binding domain, exclusive binding to heterodimeric com-
plexes and affinity for multiple cyclin/CDK complexes.
The InK4 family, consisting of p15, p16, p18, and p19, is
distinguished by loosely conserved ankyrin motifs, binding
to the catalytic subunit as well as the heterodimeric en-
zyme and exclusive association with CDK4 (or the simi-
larly acting CDK6).
In mammalian cells, proliferation control is primarily
achieved in the G1-phase of the cell cycle (Nilausen and
Green, 1965; Todaro et al., 1965; Stoker et al., 1968; Ot-
suka and Moskowitz, 1975; Matsushisa and Mori, 1981).
After G1, cells become largely independent of extracellu-
lar signals and progress automatically through subsequent
cell cycle phases to the next G1 (Todaro et al., 1965; for re-
view see Pardee, 1989). Hence, the G1 CDKs are likely to
play a particularly important role in the integration of
growth control signals with the cell cycle machinery. G1
progression is catalyzed by two enzymes: cyclin D (D1,
D2, or D3)/CDK4 and cyclin E/CDK2 (for review see
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Sherr, 1994). Both enzymes regulate independent (Oht-
subo et al., 1995; Resnitzky and Reed, 1995) and essential
(Baldin et al., 1993; Pagano et al., 1993; Ohtsubo et al.,
1995) events for G1 completion. Experimental manipula-
tion of the activities of G1 CDKs by ectopic cyclin expres-
sion has revealed a critical role for these enzymes in the
regulation of intrinsic G1 processes. For example, overex-
pression of cyclin D1 (Quelle et al., 1993; Resnitzky et al.,
1994) or cyclin E (Ohtsubo and Roberts, 1993; Resnitzky
et al., 1994) shortens G1 and decreases the G1 cell size.
Cyclin overexpression experiments suggest that G1 CDKs
are also important in coupling extracellular signals with
the cell cycle leading to reduced growth factor dependence
for proliferation (Ohtsubo and Roberts, 1993; Quelle et
al., 1993). Importantly, although these observations under-
score the importance of cyclins in the regulation of CDK
activity, they do not address how this activity is regulated
physiologically.
The CKI p21 (El-Deiry et al., 1993; Gu et al., 1993;
Harper et al., 1993; Xiong et al., 1993; Noda et al., 1994)
may be a critical regulator of CDK activity. In normal
cells, a significant fraction of cyclin/CDK complexes are
found in quaternary complexes associated with p21 and
PCNA (Zhang et al., 1994
 
a
 
). Kinase activity of cyclin/
CDK complexes may be dependent on p21 stoichiometry
such that inhibition by p21 may require the association of
more than one molecule of p21 per complex (Zhang et al.,
1994
 
b
 
). Interestingly, quaternary complexes cannot be de-
tected in many transformed cells (Xiong et al., 1993), sug-
gesting that a p21 role in CDK regulation may be impor-
tant in the regulation of the normal cell cycle.
Several lines of evidence suggest that p21 may have an
especially important role in CDK2 regulation. In vitro, p21
has a very high affinity for cyclin E/CDK2 complexes (Gu
et al., 1993) and 
 
.
 
95% of the active CDK2 in normal dip-
loid fibroblasts is found associated with p21 (Harper et al.,
1995). Additionally, in 
 
Drosophila
 
, the p21/p27 homo-
logue, Dacapo (Lane et al., 1996; Nooij et al., 1996), is re-
sponsible for cyclin E/CDK2 downregulation essential for
arresting cells after endocycle 16 (Nooij et al., 1996). Fi-
nally, we have shown previously that p21 is necessary for
CDK2 inhibition in response to p53 activation by 
 
g
 
-irradi-
ation (Brugarolas et al., 1995).
The only essential function of cyclin D/CDK4 for G1
progression is the inactivation of the growth suppressive
properties of the retinoblastoma protein, pRB. Although
inhibition of cyclin D/CDK4 activity arrests cells with
functional pRB, 
 
Rb
 
-deficient cells are not arrested by such
treatments (Lukas et al., 1994, 1995). In its unphosphory-
lated form, pRB binds and inhibits the transcription factor
E2F/DP (Chellappan et al., 1991). Upon phosphorylation,
pRB releases E2F/DP, which then activates the expression
of genes important for G1 completion and DNA replica-
tion (for review see Weinberg, 1995). Furthermore, over-
expression of E2F1 is sufficient to drive quiescent cells
into S-phase (Johnson et al., 1993). Although other pro-
teins are known to associate with pRB in its unphosphory-
lated state, their significance in G1 progression is not clear
(for review see Weinberg, 1995). The lack of requirement
of 
 
Rb
 
2/2
 
 cells for cyclin D/CDK4 suggests that these cells
might not be responsive to growth control signals that act
through cyclin D/CDK4. For example, exposing wild-type
cells to low concentrations of growth factors results in the
decreased expression of D-type cyclins (Matsushime et al.,
1991), and consequently decreased CDK4 activity, leading
to G1 arrest (for review see Sherr, 1995). In contrast, 
 
Rb
 
2/2
 
cells are capable of growth in somewhat reduced concen-
trations of growth factors (Lukas et al., 1995). However,
 
Rb
 
2/2
 
 cells are not tumorigenic indicating that they have
not lost all the mechanisms of growth control (Brugarolas,
J., and T. Jacks, unpublished data). One candidate to regu-
late proliferation in 
 
Rb
 
2/2
 
 cells is cyclin E/CDK2. In fact,
inhibition of cyclin E/CDK2 arrests cells irrespective of 
 
Rb
 
status (Ohtsubo et al., 1995). Furthermore, in 
 
Drosophila,
 
the ability of ectopically expressed E2F to drive cells into
S-phase is dependent on cyclin E (Duronio et al., 1995).
Thus, 
 
Rb
 
2/2
 
 cells are likely to be susceptible to growth
control signals that modulate CDK2 activity.
Here, we analyze the functions of p21 and pRB in the
regulation of G1 and in the coupling of extracellular sig-
nals with the cell cycle. We have studied the role of p21
and pRB using mouse embryo fibroblasts (MEFs) that are
deficient for these genes. The analysis of MEFs from
knockout mice allows us to study the function of a specific
gene, or subset of genes, in a very physiological context,
using a primary cell population that has not accumulated
other mutations, and with the rigor of tissue culture assays.
For the experiments described here, we have generated
 
p21
 
2/2
 
, 
 
Rb
 
2/2
 
, 
 
Rb
 
2/2
 
;p21
 
2/2
 
, and wild-type MEFs from lit-
termate embryos. The analysis of these cell types has re-
vealed critical roles for p21 and pRB in G1 and in the reg-
ulation of pathways that are critical for the integration of
growth control signals with the cell cycle machinery.
 
Materials and Methods
 
MEF Generation and Cell Culture
 
MEFs were generated from 12.5 days post-coitum mouse embryos. Em-
bryos were harvested, the brain and internal organs were removed and the
carcasses were minced and incubated with trypsin for 30–45 min at 37
 
8
 
C.
Tissue culture media (DME supplemented with 10% heat-inactivated
FCS [IFS], 5 mM glutamine, and penicillin/streptomycin) was added to the
cell suspension and the cells were further disaggregated. Homogeneous
cell suspensions were added to T75 flasks containing 20 ml of media. After
3–4 d in an incubator at 37
 
8
 
C, confluent cultures were trypsinized and re-
plated onto two T175 flasks containing 50 ml of tissue culture media. Af-
ter 3 d cells were frozen at 2–3
 
 3 
 
10
 
6 
 
cells per vial in DME supplemented
with 10% IFS and 10% DMSO. Cells were frozen at 
 
2
 
80
 
8
 
C and stored at
 
2
 
150
 
8
 
C. Vials were subsequently thawed and cells expanded every 3 d.
Cells were seeded at 1.5–2
 
 3 
 
10
 
6
 
 cells per 10-cm dish or equivalent. Early
passage (
 
P
 
 , 
 
6) MEFs were used for all the experiments.
 
Genotyping
 
PCR to detect 
 
Rb
 
 status was performed as described previously (Jacks et al.,
1992). The following primers were used to determine the 
 
p21
 
 genotype: 5
 
9
 
AAG CCT TGA TTC TGA TGT GGG C 3
 
9
 
 (for both the wild-type and
the mutant allele), 5
 
9
 
 TGA CGA AGT CAA AGT TCC ACC G 3
 
9
 
 (spe-
cific to the wild-type allele) and 5
 
9
 
 GCT ATC AGG ACA TAG CGT
TGG C 3
 
9
 
 (specific to the mutant allele). 10
 
3
 
 PCR buffer: 500 mM KCl,
100 mM Tris (pH 8.3), 15 mM MgCl, 1 mg/ml BSA, 2 mM dNTPs. Ther-
mocycling: step 1, 4 min at 94
 
8
 
C; step 2, 40 cycles of 1 min at 72
 
8
 
C, 1 min at
64
 
8
 
C and 3 min at 72
 
8
 
C; step 3, 7 min at 72
 
8
 
C. Polynucleotides were sepa-
rated in a 2% agarose gel with the wild-type being 
 
z
 
900 bp and the mu-
tant band being 
 
z
 
750 bp.
 
G0 Synchronization
 
1.5–2 
 
3 
 
10
 
6
 
 MEFs were plated in 10-cm dishes and grown to confluency 
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for 4 d in media supplemented with 10% IFS. Fibroblasts were washed
with PBSA and incubated for an additional 4 d in media supplemented
with 0.1% IFS.
 
Cell Cycle and Cell Size Analysis
 
Asynchronously growing cells were washed with PBSA, trypsinized, and
fixed in 70% methanol at 
 
2
 
20
 
8
 
C for several hours. Cells were centrifuged
at 2,000 rpm and resuspended in PBS containing RNase A (Sigma Chemi-
cal Co., St. Louis, MO) at 0.1 mg/ml. Samples were incubated at 37
 
8
 
C for
15–30 min and propidium iodide (PI; Sigma Chemical Co.) was added to
final concentration of 0.2 mg/ml. After 6 h at 4
 
8
 
C, samples were processed
by a FACScan
 
®
 
 (Becton Dickinson, Mountain View, CA). Data was ana-
lyzed with ModFit LT software (Becton Dickinson). Cell size analysis was
performed on 2n and 4n DNA containing populations gated from a
foward light scatter height (FSC-H)/FL2-A dot plot and represented in a
FSC-H histogram. To analyze the cell cycle distribution, cells were pulsed
for 5 h with 0.3 
 
m
 
g/ml 5-bromodeoxiuridine (BrdU; Sigma Chemical Co.)
and 0.03 
 
m
 
g/ml 5-fluoro-5-deoxiuridine (Sigma Chemical Co.). Samples
were processed as described in Brugarolas et al. (1995).
 
Soft Agar Assays
 
50,000 cells synchronized in G0 were resuspended in 0.34% low melting
point agarose (LMP agarose; GIBCO BRL, Gaithersburg, MD) in DME
supplemented with 20% IFS. Cells were plated onto 6-cm dishes coated
with 3% LMP agarose in DME plus 20% IFS. Cultures were maintained
in an incubator at 37
 
8
 
C and were supplemented with 2 ml of 0.34% LMP
agarose in DME containing 20% IFS every 2 d. Samples were analyzed
for colony formation at 3 wk.
 
Suspension Cultures
 
Suspension cultures were performed as described previously (Guadagno
and Assoian, 1991), with some modifications. 3.5
 
 3 
 
10
 
6 
 
G0 synchronized
cells were resuspended in media supplemented with 20% IFS and plated
onto agarose-coated plates (0.8% agarose [GIBCO BRL] in DME supple-
mented with 20% IFS). Cells were harvested for protein extracts after 3 d
using a rubber policeman.
 
Focus Formation Assay
 
Cells from two different strains of 
 
Rb
 
2/2
 
;
 
p21
 
2/2
 
 and 
 
Rb
 
2/2
 
 MEFs were
seeded with wild-type MEFs in 10-cm dishes at a ratio 1:100. Media was
changed every 3 d, and the cultures were followed for four weeks.
 
Immunoblotting
 
Protein extracts were prepared as described (Zhu et al., 1996). Protein
concentration was evaluated with the BioRad protein assay. 300 
 
m
 
g of
protein were fractionated by SDS-PAGE and transferred to Immobilon-P
(Millipore Corp., Waters Chromatography, Bedford, MA) or nitrocellu-
lose (MSI, Westboro, MA). Membranes were blocked in TBS-T (10 mM
Tris [pH 7.5], 150 mM NaCl, 0.03% Tween-20) containing 5% nonfat dry
milk. Cyclin D1 was detected using a mouse anti-cyclin D1 antibody (HD-
11; Santa Cruz Biotechnology, Santa Cruz, CA) at 0.5 
 
m
 
g/ml, a secondary
rabbit anti–mouse IgG antibody (Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA) at 0.2 
 
m
 
g/ml and a tertiary anti–rabbit IgG antibody
conjugated to HRP (Amersham Pharmacia Biotechnology Inc., Piscat-
away, NJ) at a dilution 1:6,000. p27 detection was performed using a goat
anti-p27 antibody (C-19-G; Santa Cruz Biotechnology) at 0.5 
 
m
 
g/ml, a sec-
ondary mouse anti–goat IgG antibody (Jackson ImmunoResearch Labo-
ratories) at 0.2 
 
m
 
g/ml and a tertiary antibody against mouse IgG conju-
gated to HRP (Amersham Pharmacia Biotechnology Inc.) at 1:6,000. P21
and pRB were detected using Santa Cruz C-19-G and PharMingen G3-245
antibodies, respectively. Detection was performed by chemiluminescence.
 
In Vitro Kinase Assays
 
CDK2 and CDK4 in vitro kinase assays were performed as described pre-
viously (Matsushime et al., 1994) with the following modifications. Cell ly-
sates (between 180–450 
 
m
 
g of protein were used for CDK2 kinase assays
and between 0.8–1.3 mg of protein were used for CDK4 kinase assays)
were precleared with equilibrated protein A beads (Pierce Chemical Co.,
Rockford, IL) and incubated with anti-CDK4 (C-22; Santa Cruz) or anti-
CDK2 (kindly provided by G.J. Hannon, Cold Spring Harbor Laboratories,
Cold Spring Harbor, NY) for 4 h. Immune complexes were precipitated
with protein A beads (Pierce Chemical Co.) and incubated in the kinase
buffer containing 4 mM ATP, 20 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP (NEN-Dupont, Boston,
MA) and 6 
 
m
 
g of GST-RB (GST fusion with aminoacids 792–928 from the
COOH terminus of pRB) or 2 
 
m
 
g of histone H1 (Sigma Chemical Co.), for
30–60 min at 30
 
8
 
C. Quantitation was performed by phosphorimager analysis.
 
Tumorigenicity Assays
 
Fibroblasts were trypsinized, washed with PBSA, and resuspended at 1
 
 3
 
10
 
7
 
 cells/ml in PBSA. 2
 
 3 
 
10
 
6
 
 cells were injected subcutaneously into two
flanks of three 5-wk-old Swiss nu/nu mice (Taconic Farms Inc., German-
town, NY). Mice were monitored for 6 mo.
 
Pathology Analysis
 
Over 20 
 
Rb
 
1/2
 
;
 
p21
 
2/2
 
 mice were examined histologically for tumors in the
CNS, retina, pituitary gland, thyroid gland, salivary gland, trachea, lungs,
heart, stomach, small and large intestine, liver, pancreas, spleen, testis,
prostate, ovaries, uterus, mammary gland, skin, bone, kidneys, and
adrenals. Blood samples were also collected for analysis.
 
Results
 
p21 Is a Physiological Inhibitor of CDK2
 
In an effort to characterize the cell cycle effects of muta-
tions affecting the CDK4 and CDK2 regulatory pathways,
we first determined the consequences of 
 
p21
 
 mutation in
primary cells in culture using a variety of assays. Although
found in normal cells associated with multiple CDKs
(Xiong et al., 1992; Harper et al., 1993), p21 does not bind
all of them with equal affinity (Harper et al., 1995), sug-
gesting differential regulation by p21. In vitro, p21 has a
very high affinity for complexes containing CDK2 and
CDK4 (Harper et al., 1995). To examine the role of p21 in
the regulation of these G1 CDKs, we determined CDK4
and CDK2 kinase activities in exponentially growing 
 
p21
 
2/2
 
and wild-type control MEFs generated from littermate
embryos. Protein extracts were prepared and precleared
of nonspecific kinase activity, and CDK4 and CDK2
immunoprecipitates were incubated in the presence of
 
g
 
-[
 
32
 
P]ATP
 
 
 
 and a vast excess of GST-RB as a kinase sub-
strate. As shown in Fig. 1 
 
A
 
, the catalytic activity of CDK4
was very similar in 
 
p21
 
2/2
 
 and wild-type cells. Therefore,
in exponentially growing fibroblasts, p21 does not appear
to be a major CDK4 inhibitor. In contrast, CDK2 activity
in 
 
p21
 
2/2
 
 cells was elevated two- to fourfold compared
with wild-type cells (Fig. 1, 
 
B
 
 and 
 
C
 
). This increased activ-
ity in 
 
p21
 
-deficient cells could not be accounted for by in-
creased levels of cyclin E, cyclin A, or CDK2 (data not
shown). Furthermore, 
 
.
 
50% of CDK2 in wild-type MEFs
was found associated with p21 (data not shown), providing
support to the idea that the effect of p21 loss on CDK2 ac-
tivity is direct. Thus, in exponentially growing fibroblasts
in tissue culture, p21 is a critical inhibitor of CDK2.
pRB is phosphorylated by CDK2 containing complexes
both in vitro and in vivo (for review see Weinberg, 1995);
pRB phosphorylation results in a retarded migration in
SDS-PAGE. Western blot analysis of pRB from extracts
of wild-type and 
 
p21
 
2/2 cells normalized for protein con-
tent revealed an increase in the slow migrating form of
pRB in p212/2 as compared with wild-type cells (Fig. 1 D),
suggesting that pRB is phosphorylated to a greater extent
in p212/2 than in wild-type cells. This increase in pRB
phosphorylation is likely to reflect the increased CDK2 ac-The Journal of Cell Biology, Volume 141, 1998 506
tivity observed in p212/2 as compared with wild-type cells
in the in vitro CDK2 kinase assays.
p212/2 Cells Show Altered G1 Regulation
Because p212/2 cells have higher levels of CDK2 activity
than wild-type cells, we sought to determine whether they
would exhibit a decreased G1 length as has been shown
for cells overexpressing cyclin E (Ohtsubo and Roberts,
1993). Cultures of p212/2 and wild-type MEFs were la-
beled with the thymidine analogue BrdU for 5 h, fixed,
stained with the DNA intercalating agent PI, and assayed
by two-dimensional FACS® analysis. Table I shows the re-
sults from four independent experiments. The analysis of
the distribution of p212/2 and wild-type cells showed that
the percentage of mutant cells in G1 compared with wild-
type cells was modestly decreased by 5.2% (Table I).
These data suggest that the length of G1, compared with
the overall cell cycle length, is shorter in p212/2 cells than
in wild-type cells.
Elevated levels of CDK2 activity have also been shown
to reduce the G1 cell size (Ohtsubo and Roberts, 1993),
which might be a consequence of the G1 shortening. To
analyze the size of p212/2 cells, asynchronously growing
p212/2 and wild-type cells were fixed, stained with PI, and
analyzed by FACS®. The PI staining allowed us to corre-
late DNA content with cell size. Comparative analysis of
the cell size between wild-type and p212/2 cells revealed
that p212/2 cells contained a larger percentage of cells with
smaller size (assessed by forward scatter, FSC-H; Fig. 2
A). Note that FSC-H gives an indication of diameter and
that small differences in diameter represent larger differ-
ences in volume. The cell size distribution of p212/2 cells
with a 2n DNA content (i.e., in G1) was shifted towards
the left of that of wild-type cells (Fig. 2 B) accounting for
the increased number of smaller cells observed in Fig. 2 A.
Interestingly, despite clear differences in G1 cell size, the
size distribution of p212/2 and wild-type cells with a 4n
DNA content was very similar (Fig. 2 E). Thus, between
the beginning of S-phase and before cytokinesis, some of
the p212/2 cells would seem to increase in size to a larger
extent than wild-type cells, apparently compensating for
the smaller 2n cell size.
Additive Effects of the Rb and p21 Mutations in
the G1-Phase
The phenotype of p212/2 cells is reminiscent of the pheno-
type that has been previously reported for Rb2/2 MEFs
(Lukas et al., 1995; Herrera et al., 1996). To compare the
role of p21 and pRB in the regulation of G1, we generated
Rb2/2 and p212/2 littermate embryos from p211/2;Rb1/2
crosses and derived MEFs from them. These cells were
then analyzed in the assays described above. Rb2/2 MEFs
have similar levels of CDK4 and CDK2 kinase activities to
wild-type MEFs (Lukas et al., 1995; Fig. 1). The analysis of
the cell cycle phase distribution of Rb2/2 cells indicated a
pattern remarkably similar to that of p212/2 cells (Table
I). Previously, Rb-deficient MEFs were shown to be
smaller than wild-type MEFs (Herrera et al., 1996; Fig. 2 A);
we have found that this decrease in size is due to a de-
crease in the size of G1 cells (Fig. 2 B). As with p212/2
cells, the size distribution of cells with a 4n DNA content
was similar between Rb2/2 and wild-type cells (Fig. 2 E).
Rb2/2 cells contain several-fold higher levels of cyclin E
compared with wild-type cells, which is thought to reflect
increased E2F activity (Herrera et al., 1996). This in-
creased cyclin E, paradoxically, does not result in a pro-
portional increase in cyclin E–associated CDK2 activity,
although the activity is elevated in Rb2/2 cells in G1 (Her-
rera et al., 1996). We have found that Rb2/2 cells also con-
tain several-fold higher levels of p21 as compared with
wild-type cells (Fig. 1 D). This increase in p21 may also re-
flect increased E2F transcriptional activity as E2F-1 has
been shown to specifically transactivate the p21 promotor
Figure 1. CDK2 and CDK4 catalytic activities from asynchro-
nously growing wild-type (Wt), p212/2, Rb2/2, and Rb2/2;p212/2
cells. (A) In vitro CDK4 kinase assay using GST-RB as a substrate.
(B) In vitro CDK2 kinase assay using GST-RB as a substrate. (C)
Histogram representing quantitative analysis of the results from
the CDK2 kinase assay. (D) Western blot analysis of p21 and
pRB in wild-type, p212/2, and Rb2/2 cells. Lanes shown were re-
assembled in appropriate order from a single autoradiogram. All
samples were derived from the same experiment.
Table I. Cell Cycle Distribution
% G1 % S-phase % G2/M
Wt 47.2 6 0.6 41 6 0.9 11.8 6 0.9
p212/2 42 6 2.2 44.5 6 2.1 12.8 6 1.1
Rb2/2 42.2 6 4.4 45.5 6 4.7 12.6 6 1.1
Rb2/2;p212/2 35.6 6 2.8 50.8 6 2.8 13.6 6 0.4
Analysis of the cell cycle distribution of asychronously growing wild-type, p212/2,
Rb2/2, and Rb2/2;p212/2 cells. Cells were pulsed with 5 BrdU for 5 h, fixed, stained
with PI and analyzed by two-dimensional FACS® analysis. The data shows the aver-
age of four independent experiments and standard deviations of the measurements.Brugarolas et al. Proliferation Control by pRB and p21 507
(Hiyama et al., 1997). Thus, increased p21 levels may re-
sult in the downregulation of CDK2 activity and could ex-
plain why cyclin E associated CDK2 activity does not in-
crease proportionally to cyclin E levels.
Next we examined whether combined dysregulation of
CDK2 (through mutation of p21) with disruption of
CDK4 (through Rb mutation) pathways would cause addi-
tional G1 phase defects. Constitutive activation of these
two pathways through these mutations might also be ex-
pected to limit the ability of cells to stop the cell cycle ma-
chinery in response to extracellular growth inhibitory sig-
nals. To test these possibilities, we generated embryos
deficient in both genes and isolated MEFs from them.
p212/2;Rb2/2 embryos were generated from intercrosses
of p212/2;Rb1/2 mice. From these crosses, however, all re-
sulting MEF populations were homozygous mutant for
p21. Therefore, to generate wild-type, Rb2/2 as well as
p212/2 control embryos from the same litter as the p212/2;
Rb2/2 mutants, we also intercrossed a large series of p211/2;
Rb1/2 animals.
Rb2/2;p212/2 cells (similar to p212/2 cells) had two- to
fourfold higher levels of CDK2 activity compared with
Rb2/2 or wild-type cells (Fig. 1, B and C). Comparative
analysis of the cell cycle distributions of Rb2/2;p212/2 cells
indicated a further reduction in the percentage of cells in G1;
while the number of cells in G1 in p212/2 and Rb2/2 cells
was decreased by 5.2 and 5%, respectively, it was reduced
by 11.6% in double mutant cells (Table I). Conversely, the
double mutant cells showed an increase in the percentage
of cells in S-phase and G2/M that was approximately twice
that seen in comparing single mutant to wild-type cells (Ta-
ble I). These data indicate that loss of pRB and p21 have ad-
ditive effects in G1-phase regulation. Cell size analysis re-
vealed that the cell size distribution of Rb2/2;p212/2 cells is
shifted towards the left of that of single mutant cells (Fig. 2
A). This seems to be due to an increase in the proportion
of smaller G1 cells (Fig. 2 C). Because of the relatively
small changes in cell diameter, we analyzed the size of
Rb2/2;p212/2 cells derived from two different embryos. As
shown in Fig. 2 D, the size of cells from these two strains
was indistinguishable. As observed for the single mutant
cells, the size distribution of Rb2/2;p212/2 cells with a 4n
DNA content is similar to wild-type cells (Fig. 2 E).
We have further characterized G1 progression in Rb2/2;
p212/2 cells by analyzing the cell cycle profiles of G0 syn-
chronized double mutant and wild-type cells as they progress
to S-phase. As shown in Fig. 3, A–F, double mutant cells
enter S-phase 3–4 h earlier than wild-type cells. Interest-
ingly, however, the reduced G1 length was not associated
with a significant change in the population doubling time.
When compared in standard growth curve analysis, double
mutant cells accumulated with similar kinetics to Rb2/2,
p212/2, and wild-type cells (Fig. 3 G). These data suggest
that the decrease in G1 length does not lead to a reduction
in overall cell cycle length, perhaps due to compensatory
effects in the S and G2/M phases; such effects would be in-
dicated from the cell size analysis described above.
Decreased Serum Dependence for Proliferation of
Rb2/2;p212/2 Cells
G1 CDKs are candidates to integrate extracellular signals
with the cell cycle. Thus, mutations in constitutive regula-
tory elements of these pathways may impair the cell’s abil-
ity to regulate the cell cycle machinery in response to ex-
tracellular signals. To test this possibility, we analyzed the
effects of loss of pRB and p21 in serum responsiveness.
The growth properties of Rb2/2;p212/2, p212/2, Rb2/2, and
wild-type MEFs were characterized in the presence of lim-
iting quantities of serum. Cells were synchronized in G0
and plated at low density in 0.1 and 0.5% FCS. Duplicate
samples were collected on five consecutive days and
counted. As expected, no increase in cell number occurred
in wild-type cells in 0.1% FCS and only a very small in-
crease was observed in 0.5% FCS (Fig. 4, A and B). p212/2
cells were capable of some proliferation at both serum
Figure 2. Cell size analysis of wild-type, p212/2, Rb2/2, and Rb2/2;
p212/2 MEFs. Asynchronously growing cells were harvested,
fixed, stained with PI and analyzed by FACS®. 60,000 events
were collected for each sample. 2n and 4n DNA containing popu-
lations were gated for cell size analysis in a FSC-H by FL2-A dot
plot and scored in a FSC-H histogram. (A) Cell size analysis of
wild-type, p212/2, Rb2/2, and Rb2/2;p212/2 cells. (B and C) Cell
size analysis of wild-type, p212/2, Rb2/2, and Rb2/2;p212/2 cells
with a 2n DNA content. (D) Size analysis of two strains of Rb2/2;
p212/2 cells with a 2n DNA content. These strains were derived
from two different embryos. (E) Cell size analysis of wild-type,
p212/2, Rb2/2, and Rb2/2;p212/2 cells with a 4n DNA content.The Journal of Cell Biology, Volume 141, 1998 508
concentrations, as were Rb2/2 cells (Fig. 4, A and B).
Strikingly,  Rb2/2;p212/2 cells had a significant growth ad-
vantage over either single mutant strain, as well as wild-
type cells (Fig. 4, A and B). Similar results were obtained
in 0.05 and 0.3% FCS (data not shown). However, Rb2/2;
p212/2 cells still exhibited a significant dependence on se-
rum for proliferation as observed by comparing the growth
rate of these cells in 0.5 and 5% FCS (Fig. 4 C). It is impor-
tant to note that these data do not demonstrate that p21
and pRB are direct regulators of the serum response path-
way, only that mutations in constitutive regulators of G1
CDK pathways affect the ability of cells to arrest in the
presence of concentrations of growth factors insufficient
for normal cell proliferation.
Loss of pRB and p21 Is Sufficient for
Anchorage-independent Growth
Fibroblast cell proliferation is contingent upon adhesion
and spreading onto an adequate substratum (Green and
Nilausen, 1962; for review see Assoian, 1997). Plating cells
in semisolid medium results in a G0/G1 arrest (Otsuka and
Moskowitz, 1975; Matsushisa and Mori, 1981; Guadagno
and Assoian, 1991) that is thought to be mediated through
the downregulation of CDK4 and CDK2 activities (for re-
view see Assoian, 1997). Because Rb2/2;p212/2 cells should
not require cyclin D/CDK4 activity for proliferation and
exhibit two- to fourfold higher levels of CDK2 activity than
wild-type cells, we investigated whether these cells retain
the ability to arrest in nonadherent conditions. Rb2/2;
p212/2 MEFs from two different embryos were assayed for
anchorage-independent growth in soft agar. p212/2, Rb2/2,
and wild-type MEFs derived from littermate embryos
were used as controls. Cells of each genotype were plated
onto dishes coated with 3% LMP agarose in media con-
taining 20% FCS and allowed to grow for 3 wk. Cultures
were supplemented with 0.3% LMP agarose in media con-
taining 20% FCS every 3 d. Although the different control
cells failed to grow under these conditions (Fig. 5, A–C
and E–G), Rb2/2;p212/2 were capable of forming colonies
Figure 3. Cell cycle analysis of G0-S
phase interval in Rb2/2;p212/2 and
wild-type MEFs and growth rates of
Rb2/2;p212/2, Rb2/2, p212/2, and wild-
type cells. (A–F) DNA content profiles
of synchronous cultures of wild-type
and  Rb2/2;p212/2 cells at different
times after release from G0. (G)
Growth properties of Rb2/2;p212/2,
Rb2/2,  p212/2, and wild-type MEFs de-
rived from littermate embryos in tissue
culture media supplemented with 10%
FCS. Values at different timepoints
represent the average of the measure-
ments from duplicate samples. This ex-
periment was performed three times
with duplicate samples with similar re-
sults.
Figure 4. Growth properties
of wild-type, p212/2, Rb2/2,
and  Rb2/2;p212/2 cells in the
presence of limiting concen-
trations of growth factors. (A
and  B) Cells were synchro-
nized in G0 and replated at
low density in 0.1 or 0.5%
FCS. At the indicated times,
duplicate samples were har-
vested and counted. Similar
results were obtained at 0.05
and 0.3% FCS (data not
shown). (C) Comparative
analysis of the growth prop-
erties of Rb2/2;p212/2 cells in
0.5 and 5% FCS.Brugarolas et al. Proliferation Control by pRB and p21 509
(Fig. 5, D and H). Colony size varied but some colonies
were quite large (Fig. 5 H). These data demonstrate that
loss of both pRB and p21 is sufficient to allow anchorage-
independent growth, whereas the presence of either inhib-
itor singly still allows growth arrest.
Plating cells on standard agarose prevents cell spreading
and allows the retrieval of cells for biochemical analysis
(Guadagno et al., 1993). Fibroblasts plated under these
conditions downregulate cyclin D1 (Bohmer et al., 1996;
Zhu et al., 1996) the major D-type cyclin in fibroblasts
(Won et al., 1992) and inhibit cyclin E/CDK2 activity
(Fang et al., 1996; Zhu et al., 1996). Cyclin E/CDK2 inhibi-
tion is not caused by downregulation of cyclin E levels or
by inhibitory phosphorylation of CDK2 (Fang et al., 1996),
but instead is thought to be mediated by p21 and p27
(Fang et al., 1996; Zhu et al., 1996). However, p21 and p27
were only somewhat induced in anchorage-independent
conditions (Fang et al., 1996; Zhu et al., 1996); increased
Figure 5. Anchorage-depen-
dence for growth of wild-type,
p212/2,  Rb2/2, and Rb2/2;p212/2
cells. G0 synchronized popula-
tions were plated in soft agar
and colony formation was
scored after 3 wk. Bars: (A–D
and  E–H) 500 mm.The Journal of Cell Biology, Volume 141, 1998 510
levels of p21 and p27 bound to cyclin E/CDK2 may result
from an increase in the pool of free inhibitors due to the
decreased levels of cyclin D1/CDK4 complexes (for re-
view see Assoian, 1997).
Similar to 3T3 fibroblasts, MEFs responded to anchor-
age-independent conditions with a reduction in cyclin D1
levels (Fig. 6 A) and an inhibition of CDK2 (Fig. 6, C and
D). As with 3T3 cells, the levels of p21 and p27 in MEFs
did not change significantly under these conditions (Fig. 6 B
and data not shown), suggesting again that CDK2 inhibi-
tion may be due to a redistribution of the CKIs. In an ef-
fort to understand the molecular mechanisms that under-
lie the ability of Rb2/2;p212/2 cells to grow in soft agar, we
characterized CDK activity biochemically. Protein ex-
tracts from Rb2/2;p212/2 and wild-type control cells in
monolayers and in suspension were normalized for protein
content and used for Western blot analysis and kinase as-
says. As shown in Fig. 6, double mutant MEFs downregu-
lated cyclin D1 and CDK2 activity under these conditions.
However, Rb2/2;p212/2 cells failed to downregulate CDK2
activity to wild-type levels (Fig. 6, C and D). In fact, the
levels of CDK2 activity in nonadherent Rb2/2;p212/2 cells
were very similar to the levels present in exponentially
growing wild-type cells. The level of CDK2 activity ob-
served in double mutant cells in semisolid medium can
only be partially accounted for by loss of p21, however, be-
cause CDK2 activity in p212/2 cells under the same condi-
tions was found to be two- to fourfold higher than in wild-
type cells (Fig. 6 E), compared with the four- to sixfold
higher levels observed in the double mutants (Fig. 6, C–E).
Therefore, the remaining increase in CDK2 activity in
Rb2/2;p212/2 cells could reflect the increased proportion
of proliferating cells in these cultures.
Rb2/2;p212/2 Cells Are Susceptible to Contact 
Inhibition of Growth
Normal fibroblasts grow in monolayers and arrest with a
2n DNA content at high cell densities (Nilausen and
Green, 1965). This arrest is thought to involve p27 (Polyak
et al., 1994a; Polyak et al., 1994b; Toyoshima and Hunter,
1994), although loss of p27 does not alter the susceptibility
of MEFs to contact inhibition (Nakayama et al., 1996).
Thus, other molecules in addition to p27 must be involved
in this response. Having shown that Rb2/2;p212/2 cells do
not arrest in conditions preventing anchorage, we next
tested the susceptibility of these cells to contact inhibition
of growth. Rb2/2;p212/2, wild-type, p212/2, and Rb2/2
MEFs derived from littermate embryos were plated at 2 3
106 cells per 10-cm dish and allowed to grow to confluence
for 6 d. Cells were then harvested, fixed, stained with PI
and evaluated by FACS® analysis. As shown in Fig. 7, all
cultures exhibited a prominent G0/G1 peak indicative of a
cell cycle arrest. The mutant cultures had a somewhat
higher S-phase and G2/M fractions, suggesting a slightly
reduced capacity for contact inhibition. Thus, in contrast
to anchorage independence, loss of pRB and p21 is not
sufficient to overcome growth inhibitory signals triggered
by cell–cell contact.
Given the slight increase in the S-phase or G2/M frac-
tions among the mutant cells at confluence, we examined
these cells using a more stringent test for contact inhibi-
tion: the focus-formation assay. Mutant cells were plated
among wild-type cells at a 1:100 ratio and cultures were
scored at 4 wk for the presence of foci. Neither Rb2/2 or
Rb2/2;p212/2 cells were capable of forming foci under
these conditions (data not shown). Thus, by this measure
as well, combined elimination of p21 and pRB failed to al-
low escape from contact inhibition.
We have shown that the capacity of Rb2/2;p212/2 cells
to sustain anchorage-independent growth correlates with
failure to downregulate CDK2 activity to wild-type levels.
Because Rb2/2;p212/2 cells are susceptible to contact inhi-
bition of growth, they might be able to inhibit CDK2 un-
der these conditions. To test this hypothesis, CDK2 ki-
nase activity was assayed from protein extracts prepared
from contact-inhibited and asynchronously exponentially
growing Rb2/2;p212/2 and wild-type MEFs. As shown in
Fig. 8 B and C, Rb2/2;p212/2 cells at high densities down-
regulated CDK2 activity to wild-type levels. Furthermore,
under these conditions, we detected a several-fold in-
crease in p27 levels in wild-type and double mutant cells
(Fig. 8 A), suggesting that p27 upregulation may contrib-
ute to the inhibition of CDK2 at high cell densities in both
cell types.
Figure 6. Cyclin D1 and p27 protein levels, and CDK2 kinase ac-
tivity in wild-type and Rb2/2;p212/2 cells grown in monolayer
(Mn.) and in suspension (Sp.). (A) Cyclin D1 protein levels as-
sayed by Western blot analysis. (B) p27 protein levels assayed by
Western blot analysis. (C) In vitro CDK2 kinase assay using
GST-RB as a substrate. (D) Histogram representing quantitation
analysis of the results from the CDK2 kinase assay. (E) In vitro
CDK2 kinase assay of wild-type, p212/2, and Rb2/2;p212/2 cells in
suspension using GST-RB as a substrate. Lanes shown were reas-
sembled in appropriate order from a single autoradiogram. All
samples were derived from the same experiment.Brugarolas et al. Proliferation Control by pRB and p21 511
Rb2/2;p212/2 Cells Do Not Form Tumors in Nude Mice
Growth in soft agar usually correlates with tumorigenic
potential (Freedman and Shin, 1974; for review see As-
soian, 1997). Thus, to assay the tumorigenicity of Rb2/2;
p212/2 cells, 2 3 106 MEFs were injected subcutaneously
into nude mice. p532/2 cells expressing the viral oncogene
E1A and an activated ras allele (T24 H-ras; Lowe et al.,
1994) were used as a positive control. Whereas, mice in-
jected with p532/2;E1A;ras transformed cells developed
tumors within 2 wk, no tumors were evident after 6 mo in
mice injected with Rb2/2;p212/2 cells (data not shown).
Decreased Tumor Survival Rates of p212/2;Rb1/2 Mice
As another means to address the potential cooperative tu-
morigenic effects of p21 and Rb mutations, we have char-
acterized the tumor phenotype of animals with the geno-
type  p212/2;Rb1/2.  Rb1/2 mice have a strong tumor
predisposition (Jacks et al., 1992; Williams et al., 1994),
with a mean age of survival z340 d on a mixed genetic
background (C57BL/6-129/Sv; Williams et al., 1994). These
mice develop intermediate lobe pituitary and medullary
thyroid adenomas and adenocarcinomas (Jacks et al.,
1992; Williams et al., 1994), and tumors show loss of het-
erozygozity at the Rb locus (Williams et al., 1994). In addi-
tion to these tumors, chimeric mice composed of wild-type
and Rb2/2 cells also develop pheochromocytomas, indicat-
ing that the Rb mutation can also predispose to this tumor
type (Williams et al., 1994). In contrast, p212/2 mice do not
develop tumors (Deng et al. 1995) by 1.5 yr of age (data
not shown). Absence of p21 did not alter the tumor spec-
trum caused by the Rb mutation, as p212/2;Rb1/2 mice
also seemed to develop exclusively pituitary tumors, med-
ullary thyroid adenomas and adenocarcinomas and pheo-
chromocytomas (Table II). Interestingly, the mutation of
p21 did have a significant effect on the lifespan of animals
heterozygous for an Rb mutation. As shown in Fig. 9 and
Table II, the mean age of survival of p212/2;Rb1/2 mice
was 261 d compared with 340 d for Rb1/2 mice. Although
subtle differences in the balance of 129/Sv versus C57BL/6
alleles in these mixed genetic background animals could
contribute to this effect, it is likely that absence of p21 in-
Figure 7. Sensitivity to contact inhibition of growth of wild-type,
p212/2, Rb2/2, and Rb2/2;p212/2 cells. The left column shows rep-
resentative fields of confluent cultures. The right column shows
cell cycle profiles of confluent cultures after 6 d. 10,000 events
were collected for each sample. The data were analyzed using
ModFit LT software (Becton Dickinson). The coefficient of vari-
ation was below 6 for all the samples. Bar, 500 mm.
Figure 8. p27 protein levels and CDK2 kinase activity from expo-
nentially growing (Exp.) and confluent (Conf.) wild-type, and
Rb2/2;p212/2 cells. (A) p27 protein levels analyzed by Western
blot analysis. (B) In vitro CDK2 kinase assay using GST-RB as a
substrate. (C) Histogram representing quantitative analysis of the
results from the CDK2 kinase assay.The Journal of Cell Biology, Volume 141, 1998 512
creases the transformation potential or growth properties
of Rb2/2 cells in certain tissues, perhaps in a manner anal-
ogous to the effects reported here for fibroblasts in cul-
ture. Moreover, similar tumor size at necropsy between
Rb1/2 and p212/2;Rb1/2 mice further supports the conten-
tion that loss of p21 can accelerate tumor development in
Rb1/2 mice.
Discussion
In this manuscript, we describe the use of specific loss-
of-function mutations in two key inhibitors of the mam-
malian cell cycle to explore the mechanism of cellular re-
sponse to extrinsic factors that regulate cell cycle progression.
Previous studies using cyclin overexpression or p27 anti-
sense have demonstrated that pathways regulated by the
G1 CDKs, CDK4(6) and CDK2 are important in this pro-
cess (Ohtsubo and Roberts, 1993; Quelle et al., 1993;
Resnitzky et al., 1994; Coats et al., 1996; Rivard et al., 1996).
Our approach has been to systematically eliminate func-
tions that regulate or are regulated by these two pathways
in an attempt to render the cell insensitive to conditions
that normally elicit cell cycle arrest. From these experi-
ments, we hope to clarify the normal cellular response to
growth inhibitory conditions as well as to investigate the
relationship between the loss of normal cell cycle regula-
tion and neoplastic transformation. Taken together, our
data support a model in which regulation of G1 progres-
sion can be divided into two discrete stages controlled by
the activities of CDK4(6) and CDK2, such that inhibition
of either stage can prevent cell cycle progression. Thus, in
cells in which the CDK4(6) pathway is constitutively acti-
vated through Rb mutation and CDK2 pathway is upregu-
lated through p21 mutation, neither growth factor limita-
tion nor detachment from the substratum results in proper
cell cycle arrest.
Although capable of anchorage-independent growth,
p212/2;Rb2/2 cells are still growth arrested at high cell
densities. The difference in response to these two condi-
tions was correlated with the ability of the double mutant
cells to downregulate CDK2 activity to wild-type levels.
The more complete inhibition of CDK2 activity at conflu-
ence may be explained by the observed induction of p27,
which was not seen when the cells were prevented from
contacting the substratum. Interestingly, p27-deficient MEFs
downregulate CDK2 kinase activity to wild-type levels
(Koff, A., personal communication) and arrest at conflu-
ency (Nakayama et al., 1996). Perhaps either p21 or p27 is
sufficient for CDK2 regulation under these conditions.
This issue can be explored further by constructing p21/p27
double-mutant MEFs.
Defects in the regulation of growth in tissue culture
have been used as a measure of neoplastic transformation
(for review see Ponten, 1976; Smets, 1979), with anchor-
age-independent growth correlating well with tumorige-
nicity (Freedman and Shin, 1974; reviewed by Assoian,
1997). Interestingly, despite their ability to form colonies
in soft agar, p212/2;Rb2/2 cells were not tumorigenic in
nude mice. Thus, the loss of these two inhibitors is not suf-
ficient for proliferation in vivo. In contrast to our observa-
tions, the combination of ras activation and p21 mutation
is sufficient for transformation of mouse skin kerati-
nocytes, including the ability to form tumors in nude mice
(Missero et al., 1996). We believe that tumor formation in
nude mice by ras transformed p21-deficient keratinocytes
but not Rb2/2;p212/2 MEFs reflects critical oncogenic
functions of activated ras beyond its effects on pRB
(Peeper et al., 1997).
As indicated by the reduced life span of p212/2;Rb1/2
mice, germline mutations in these two genes can synergize
in tumor development. By analogy with our fibroblast
data, this effect could be a reflection of elevated CDK2 ac-
tivity potentiating the growth of Rb2/2 tumor cells. It ap-
pears that the loss of Rb function dictates the tumor spec-
trum, because we observed the same tumor types in
double mutant as in Rb1/2 animals. In contrast, germline
mutations in Rb and p53 produce a broader tumor spec-
trum than either of the single mutants (Williams et al.,
1994; Harvey, 1995). Therefore, although p21 is a key
downstream target of p53 in growth arrest, it appears that
the major tumor suppressor function(s) of p53 do not re-
quire p21. The acceleration of tumorigenesis in p212/2;
Rb1/2 mice indicates a context in which p21 function does
limit tumor cell growth, and could represent another
mechanism of tumor suppression by p53; this model would
assume that p53 is the major regulator of p21 expression in
some tumor types.
The integrity of the CDK4 and CDK2 pathways is not
Figure 9. Survival curve of p212/2;Rb1/2 mice (n 5 70) compared
with Rb1/2 mice (n 5 50; Williams et al., 1994) in a mixed C57BL/
6-129/Sv genetic background.
Table II. Tumor Analysis in p212/2;Rb1/2 Mice
Rb1/2 p212/2;Rb1/2
M.A.S. 340 (n 5 50) 261 (n 5 57)
Pituitary tumor 200/200 27/27
Medullary thyroid tumor 19/27 23/26
Pheochromocytoma ND 7/19
Tumor analysis in p212/2;Rb1/2 mice compared to Rb1/2 mice (Williams et al.,
1994). M.A.S., Mean age of survival.Brugarolas et al. Proliferation Control by pRB and p21 513
only critical in the regulation of cell cycle progression in
response to extracellular signals but also in response to in-
trinsic cues and senescence. Thus, p21 and pRB are re-
quired for the integrity of the p53-mediated G1 arrest re-
sponse to DNA damage (Slebos et al., 1994; Brugarolas
et al., 1995; Deng et al., 1995), and loss of p21 (Brugarolas,
J., and T. Jacks, unpublished data) or INK4a (Serrano et
al., 1996) greatly enhance the life span of MEFs in tissue
culture. In addition, Serrano et al. (1997) have recently re-
ported that overexpression of the ras oncogene can induce
a senescence-like state, in a manner dependent on both
INK4a and p53 function. Therefore, mutations in the regu-
latory elements of the CDK4 and CDK2 (Keyomarsi and
Pardee, 1993; Kitahara et al., 1995; Porter et al., 1997)
pathways may not only be sufficient to overcome extracel-
lular growth inhibitory signals but also intracellular growth
inhibitory signals and senescence, and it might be expected
that regulatory elements of these pathways would be criti-
cal targets for tumorigenesis (for review see Hirama and
Koeffler, 1995).
Tumor cells proliferate autonomously, independently of
growth inhibitory signals, and despite the absence of
growth-promoting signals. Thus, tumor cells are defective
in the integration of extracellular signals with the cell cycle
machinery. These defects lie at multiple levels, in cell sur-
face receptors, signal transduction pathways, and cell cycle
regulators. We have studied the role of two inhibitors of
G1 progression in this process. Our data support the con-
clusion that proliferation control is primarily accom-
plished in G1 and that p21 and pRB are critical compo-
nents of these regulatory pathways. We have shown that in
the absence of pRB, CDK2 can act as the gatekeeper that
secures some degree of proliferation control. We postulate
that constitutive activation of the CDK4 and CDK2 path-
ways is sufficient for unrestrained proliferation and may
render cells unable to execute a senescence triggered ar-
rest. A better understanding of the mechanisms that coor-
dinate extracellular growth control signals with the cell cy-
cle machinery in the normal cell is of primary importance
to understand how growth autonomy is achieved in cancer.
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